Emerging Paradigm of Primary Immunodeficiency Disease: Individualizing Immunoglobulin Dose and Delivery to Enhance Outcomes

Publication Date

2014

Journal Title

J Clin Immunol

Abstract

An emerging paradigm for the treatment of primary immunodeficiency disease (PIDD) with immunoglobulin (IgG) replacement therapy emphasizes the tailoring of treatments to each patient with the goal of preventing infections and minimizing side effects. Increasing evidence shows that the IgG dose needed to prevent infection varies with each patient, and both intravenous immunoglobulin (IGIV) and subcutaneous immunoglobulin (IGSC) have emerged as feasible modes of delivery. Although IGIV is currently the routine treatment, IGSC is increasingly being chosen as the preferred route of delivery due to greater flexibility and reduced side effects.

Volume Number

37

Issue Number

2

Pages

190-196

Document Type

Article

EPub Date

2014/01/31

Status

Faculty

Facility

School of Medicine

Primary Department

General Pediatrics

Additional Departments

Molecular Medicine

PMID

24477950

DOI

10.1007/s10875-014-9990-x

For the public and Northwell Health campuses

Share

COinS